Halozyme Therapeutics, Inc. HALO · SEC Filings

website

423

Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, w...

Price102.92

Market Cap11.68 B

Float112.27 M

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

News

TYPE

HEADLINE

FILED AT

8-K

Halozyme Reports Q3 2026 Results, Raises Full-Year Guidance, and Expands ENHANZE Collaborations

Nov 5, 2026

8-K

Halozyme Therapeutics Elects James Daly to Board of Directors

Sep 30, 2026

8-K

Halozyme Therapeutics Completes $1.5 Billion Convertible Senior Notes Offering

Sep 22, 2026

8-K

Halozyme Therapeutics Prices Upsized $1.3 Billion Private Offering of Convertible Senior Notes

Sep 18, 2026

8-K

Halozyme Therapeutics Announces Proposed $1.05 Billion Convertible Senior Notes Offering

Sep 16, 2026

8-K

Halozyme Therapeutics, Inc. Appoints Dannielle Appelhans to Board of Directors

Aug 18, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

10,000,000 Shares

May 19, 2017

424B5

Risks Related to this Offering and Our Common Stock

May 18, 2017

424B5

7,692,307 Shares

Feb 5, 2014

424B5

Risks Related to this Offering and Our Common Stock

Feb 3, 2014

424B5

6,800,000 Shares

Feb 10, 2012

424B5

6,800,000 Shares

Feb 9, 2012

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Nov 18, 2025

SC TO-T/A